Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore
Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare...
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'
Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments Highlighted clinical cases that improved the safety of anti-amyloid therapy...
Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business -- To Accelerate U.S. Market
Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.ai To strengthen revenue growth of AI-based brain imaging solutions in the North American market and expand product deployment...
Neurophet and The Florey Strengthen Research Collaboration on 'Neurophet AQUA' to Advance Alzheimer's Disease Diagnosis
Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and management Joint research to enhance dementia diagnosis using the brain neurodegeneration imaging software 'Neurophet AQUA' SEOUL, South Korea,...
Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'
Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive...
Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA
Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance Introduces 'Neurophet AQUA AD,' a Total Solution for Alzheimer's Disease Treatment Prescription, at the AI Theater SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- Neurophet,...
Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA'
New features include advanced analysis of multiple sclerosis (MS) and white matter hyperintensities alongside brain atrophy analysis Accelerating global expansion with cutting-edge technology targeting MS, a prevalent condition in North America and...